143 related articles for article (PubMed ID: 19452316)
21. Clinical outcome of patients with follicular lymphoma receiving chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms.
Ghesquières H; Cartron G; Seymour JF; Delfau-Larue MH; Offner F; Soubeyran P; Perrot A; Brice P; Bouabdallah R; Sonet A; Dupuis J; Casasnovas O; Catalano JV; Delmer A; Jardin F; Verney A; Dartigues P; Salles G
Blood; 2012 Sep; 120(13):2650-7. PubMed ID: 22885164
[TBL] [Abstract][Full Text] [Related]
22. Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment.
Cartron G; Ohresser M; Salles G; Solal-Céligny P; Colombat P; Watier H
Ann Oncol; 2008 Aug; 19(8):1485-1487. PubMed ID: 18408222
[TBL] [Abstract][Full Text] [Related]
23. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
Cornec D; Tempescul A; Querellou S; Hutin P; Pers JO; Jamin C; Bendaoud B; Berthou C; Renaudineau Y; Youinou P
Ann Hematol; 2012 May; 91(5):715-721. PubMed ID: 22083514
[TBL] [Abstract][Full Text] [Related]
24. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
25. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma.
Mitroviç Z; Aurer I; Radman I; Ajdukoviç R; Sertiç J; Labar B
Haematologica; 2007 Jul; 92(7):998-9. PubMed ID: 17606457
[TBL] [Abstract][Full Text] [Related]
26. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia.
Farag SS; Flinn IW; Modali R; Lehman TA; Young D; Byrd JC
Blood; 2004 Feb; 103(4):1472-4. PubMed ID: 14563637
[TBL] [Abstract][Full Text] [Related]
27. A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.
Racila E; Link BK; Weng WK; Witzig TE; Ansell S; Maurer MJ; Huang J; Dahle C; Halwani A; Levy R; Weiner GJ
Clin Cancer Res; 2008 Oct; 14(20):6697-703. PubMed ID: 18927313
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for non-Hodgkin's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab.
Czuczman MS; Grillo-López AJ; Alkuzweny B; Weaver R; Larocca A; McLaughlin P
Leuk Lymphoma; 2006 Sep; 47(9):1830-40. PubMed ID: 17064996
[TBL] [Abstract][Full Text] [Related]
29. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
Zhang W; Gordon M; Schultheis AM; Yang DY; Nagashima F; Azuma M; Chang HM; Borucka E; Lurje G; Sherrod AE; Iqbal S; Groshen S; Lenz HJ
J Clin Oncol; 2007 Aug; 25(24):3712-8. PubMed ID: 17704420
[TBL] [Abstract][Full Text] [Related]
30. Fc gamma receptor 3a genotype in follicular lymphoma: the end of the story? Reply to "Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone". Haematologica. 2012;97(6):937-942.
Procházka V; Gazdová J; Papajík T
Haematologica; 2012 Nov; 97(11):e45; author reply e46. PubMed ID: 23125245
[No Abstract] [Full Text] [Related]
31. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
Musolino A; Naldi N; Bortesi B; Pezzuolo D; Capelletti M; Missale G; Laccabue D; Zerbini A; Camisa R; Bisagni G; Neri TM; Ardizzoni A
J Clin Oncol; 2008 Apr; 26(11):1789-96. PubMed ID: 18347005
[TBL] [Abstract][Full Text] [Related]
32. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
[TBL] [Abstract][Full Text] [Related]
33. Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.
Ganjoo KN; de Vos S; Pohlman BL; Flinn IW; Forero-Torres A; Enas NH; Cronier DM; Dang NH; Foon KA; Carpenter SP; Slapak CA; Link BK; Smith MR; Mapara MY; Wooldridge JE
Leuk Lymphoma; 2015 Jan; 56(1):42-8. PubMed ID: 24717109
[TBL] [Abstract][Full Text] [Related]
34. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
Feuring-Buske M; Kneba M; Unterhalt M; Engert A; Gramatzki M; Hiller E; Trümper L; Brugger W; Ostermann H; Atzpodien J; Hallek M; Aulitzky E; Hiddemann W
Ann Hematol; 2000 Sep; 79(9):493-500. PubMed ID: 11043420
[TBL] [Abstract][Full Text] [Related]
35. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma.
Kim DH; Jung HD; Kim JG; Lee JJ; Yang DH; Park YH; Do YR; Shin HJ; Kim MK; Hyun MS; Sohn SK
Blood; 2006 Oct; 108(8):2720-5. PubMed ID: 16609067
[TBL] [Abstract][Full Text] [Related]
36. The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura.
Ellithy HN; Ahmed SH; Shahin GH; Matter MM; Talatt M
Hematology; 2018 Apr; 23(3):169-174. PubMed ID: 28856973
[TBL] [Abstract][Full Text] [Related]
37. Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia.
Burkhardt B; Yavuz D; Zimmermann M; Schieferstein J; Kabickova E; Attarbaschi A; Lisfeld J; Reiter A; Makarova O; Worch J; Bonn BR; Damm-Welk C
Ann Hematol; 2016 Sep; 95(9):1503-12. PubMed ID: 27376362
[TBL] [Abstract][Full Text] [Related]
38. FcgammaRIIa-131R allele and FcgammaRIIIa-176V/V genotype are risk factors for progression of IgA nephropathy.
Tanaka Y; Suzuki Y; Tsuge T; Kanamaru Y; Horikoshi S; Monteiro RC; Tomino Y
Nephrol Dial Transplant; 2005 Nov; 20(11):2439-45. PubMed ID: 16221721
[TBL] [Abstract][Full Text] [Related]
39. [Influence of FcγRIIIa polymorphism on rituximab-dependent NK cell-mediated cytotoxicity to Raji cells].
Qu YH; Li Y; Wu YF; Fang JP; Huang SL; Huang Y; Wei J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct; 18(5):1269-74. PubMed ID: 21129274
[TBL] [Abstract][Full Text] [Related]
40. Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma.
Kenkre VP; Hong F; Cerhan JR; Lewis M; Sullivan L; Williams ME; Gascoyne RD; Horning SJ; Kahl BS
Clin Cancer Res; 2016 Feb; 22(4):821-6. PubMed ID: 26510856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
